Class IOngoing

Umary Acido Hialuronico recall

FDA recall D-0626-2024 · initiated Jul 18, 2024

Most serious — a reasonable probability that use will cause serious harm or death.

Why it was recalled

Marketed without Approved NDA/ANDA. FDA analysis found product to be tainted with undeclared Diclofenac and Omeprazole.

Details

Product: Umary Acido Hialuronico, Suplemento Alimenticio, 850 mg caplets, packaged in 30-count bottles.
Recalling company: MAIN PRODUCTS INC
Classification: Class I
Status: Ongoing
Type: Voluntary: Firm initiated
Distribution: Nationwide within the U.S
Initiated: Jul 18, 2024
FDA report date: Aug 14, 2024

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0626-2024 ↗

← All drug recalls